PLUS THERAPEUTICS, INC. 8-K

What Happened Plus Therapeutics, Inc. (PSTV) filed a Form 8-K on May 15, 2026 under Item 2.02 to report its results of operations and financial condition for the quarter ended March 31, 2026. The company furnished a press release announcing those first-quarter 2026 financial results as Exhibit 99.1 to the filing. The report was signed by Marc H. Hedrick, M.D., President and Chief Executive Officer.

Key Details

• Filing date: May 15, 2026 (Form 8-K, Item 2.02 reported results for Q1 ended March 31, 2026).
• Press release: Furnished as Exhibit 99.1 and incorporated by reference in the 8-K.
• Signature: Signed by Marc H. Hedrick, M.D., President and CEO.
• Exhibit note: The 8-K also includes the standard Inline XBRL cover page (Exhibit 104).

Why It Matters This filing notifies investors that Plus Therapeutics has publicly reported its quarterly earnings and other corporate updates; the press release will contain the financial metrics investors typically use (revenue, net income/loss, cash position, and any commentary on pipeline or guidance). Because the 8-K itself mainly furnishes the press release, investors should read Exhibit 99.1 for the specific numbers and management commentary to assess near-term performance and capital needs.